NovaBay Pharmaceuticals (NBY)
(Delayed Data from AMEX)
$0.73 USD
+0.04 (5.80%)
Updated Sep 26, 2024 03:59 PM ET
After-Market: $0.71 -0.02 (-2.74%) 5:18 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Brokerage Reports
NovaBay Pharmaceuticals, Inc. [NBY]
Reports for Purchase
Showing records 81 - 100 ( 109 total )
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q13 - NVC-422 Clinical Data to Come in 2H13 and Beyond
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
4Q12 - All Eyes Are on NVC-422 Clinical Data in 2013
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY.
Provider: Roth Capital Partners, Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
NeutroPhase Expanded Asian Deal Illustrates Asset Monetization
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q12 Reporting is Less Relevant While Two Trials on Track is Encouraging
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Commencement of NVC-422 in Adenoviral Conjunctivitis Phase II Trial
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
Focus is on Commencements of Conjunctivitis and Impetigo Clinical Studies
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
NVC-422 leading franchise is heading into possible inflection points
Provider: Roth Capital Partners, Inc.
Analyst: JEN Y
Company: NovaBay Pharmaceuticals, Inc.
Industry: Medical - Drugs
NVC-422 leading franchise is heading into possible inflection points
Provider: Roth Capital Partners, Inc.